MAP
BIIB icon

Moody Aldrich Partners’s Biogen BIIB Stock Holding History

Moody Aldrich Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,901
Closed -$626K – 201
2024
Q1 		$626K Sell
2,901
-709
-20% -$166K 0.11% 129
2023
Q4 		$934K Buy
3,610
+1,080
+43% +$265K 0.17% 117
2023
Q3 		$650K Buy
+2,530
New +$677K 0.12% 123

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Moody Aldrich Partners's BIIB Position: Q2 2024 in Review

Moody Aldrich Partners sold out of Biogen (BIIB) in Q2 2024, closing a stake of 2,901 shares — an estimated $626K sold.

Moody Aldrich Partners first reported a position in BIIB in Q3 2023 and held it in 3 quarters. The position peaked at $934K in Q4 2023. 943 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

  • Moody Aldrich Partners reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
  • Moody Aldrich Partners sold 2,901 Biogen shares in Q2 2024, an estimated $626K.
  • Moody Aldrich Partners first reported a position in Biogen in Q3 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's Biogen position peaked at $934K in Q4 2023.
  • 943 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Moody Aldrich Partners's 13F filing for Q2 2024, filed 24 Jul 2024.